NASDAQ:NVIV - Nasdaq - US46186M6057 - Common Stock - Currency: USD
0.3207
-0.17 (-34.28%)
The current stock price of NVIV is 0.3207 USD. In the past month the price decreased by -58.69%. In the past year, price decreased by -84.43%.
Symbol | Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABT | ABBOTT LABORATORIES | 28.89 | 234.01B | ||
ISRG | INTUITIVE SURGICAL INC | 80.74 | 211.07B | ||
BSX | BOSTON SCIENTIFIC CORP | 41.63 | 154.00B | ||
SYK | STRYKER CORP | 31.4 | 145.92B | ||
MDT | MEDTRONIC PLC | 16.84 | 115.33B | ||
BDX | BECTON DICKINSON AND CO | 16.35 | 65.30B | ||
EW | EDWARDS LIFESCIENCES CORP | 27.98 | 43.23B | ||
GEHC | GE HEALTHCARE TECHNOLOGY | 20.29 | 41.62B | ||
IDXX | IDEXX LABORATORIES INC | 40.25 | 37.07B | ||
DXCM | DEXCOM INC | 53.81 | 34.68B | ||
RMD | RESMED INC | 26.21 | 34.03B | ||
PHG | KONINKLIJKE PHILIPS NVR- NY | 17.5 | 24.02B |
Invivo Therapeutics Holdings Corp. operates as a research and clinical-stage biotechnology company, which engages in developing and commercializing biopolymer scaffolding devices for the treatment of spinal cord injuries. The company is headquartered in Cambridge, Massachusetts and currently employs 6 full-time employees. The company went IPO on 2006-11-14. The firm's Neuro-Spinal Scaffold implant is an investigational bioresorbable polymer scaffold that is designed for implantation at the site of injury within a spinal cord. The company is intended to promote appositional, or side-by-side, healing by supporting the surrounding tissue after injury, minimizing the expansion of areas of necrosis, and providing a biomaterial substrate for the body's own healing/repair processes following injury. The company is composed of two biocompatible and bioresorbable polymers that are cast to form a porous investigational product: Poly lactic-co-glycolic acid and Poly-L-Lysine. Poly lactic-co-glycolic acid is a polymer that is used in resorbable sutures and provides biocompatible support for Neuro-Spinal Scaffold implants and Poly-L-Lysine is a positively charged polymer used to coat surfaces.
INVIVO THERAPEUTICS HOLDINGS
Building 1400 East 4Th Floor, One Kendall Square
Cambridge MASSACHUSETTS 02139 US
CEO: Richard Toselli
Employees: 6
Company Website: https://www.invivotherapeutics.com/
Phone: 16178635524
The current stock price of NVIV is 0.3207 USD. The price decreased by -34.28% in the last trading session.
The exchange symbol of INVIVO THERAPEUTICS HOLDINGS is NVIV and it is listed on the Nasdaq exchange.
NVIV stock is listed on the Nasdaq exchange.
INVIVO THERAPEUTICS HOLDINGS (NVIV) has a market capitalization of 997.38K USD. This makes NVIV a Nano Cap stock.
INVIVO THERAPEUTICS HOLDINGS (NVIV) currently has 6 employees.
INVIVO THERAPEUTICS HOLDINGS (NVIV) has a resistance level at 0.63. Check the full technical report for a detailed analysis of NVIV support and resistance levels.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
NVIV does not pay a dividend.
INVIVO THERAPEUTICS HOLDINGS (NVIV) does not have a PE ratio as the earnings reported over the last twelve months were negative (-3.52).
ChartMill assigns a fundamental rating of 2 / 10 to NVIV. NVIV has a great financial health rating, but its profitability evaluates not so good.
Over the last trailing twelve months NVIV reported a non-GAAP Earnings per Share(EPS) of -3.52. The EPS increased by 56.05% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -97.39% | ||
ROE | -104.6% | ||
Debt/Equity | 0 |
ChartMill assigns a Buy % Consensus number of 86% to NVIV. The Buy consensus is the average rating of analysts ratings from 7 analysts.